IF YOU . . .

☐ HAVE BEEN DIAGNOSED WITH ER+, EARLY-STAGE BREAST CANCER
☐ WONDER IF YOUR ANTI-ESTROGEN THERAPY IS HELPING
☐ EXPERIENCE SIGNIFICANT SIDE EFFECTS
☐ WORRY ABOUT LONG-TERM HEALTH IMPACT OF TREATMENT
☐ WOULD LIKE TO KNOW THE RISK OF CANCER RETURNING

. . . THIS BROCHURE IS FOR YOU

Isn’t it time to BeWisER+ and talk to your doctor?
Breast cancer is not a 5-year disease
Risk of recurrence continues beyond 5 years for some women

Less than 1/2 of recurrences will happen BEFORE year 5

More than 1/2 of recurrences will happen AFTER year 5

Because ER+ breast cancer is not a 5 year disease, and there is a risk of the cancer returning, your doctor may recommend continuing therapy up to 10 years to help reduce that risk. Understanding your personal risk of the cancer returning will help you and your doctor create the best treatment plan for you beyond 5 years.

As you look to learn more and plan beyond 5 years, it is important to know your options.

If you were diagnosed with early-stage estrogen receptor-positive (ER+), also known as hormone receptor-positive breast cancer, this brochure is being provided to help you and your oncologist answer TWO important questions about your treatment plan after 5 years:

1. What is your personal risk of the cancer coming back after year 5?

Although ER+, early-stage breast cancer generally has a very good prognosis for most women, there is risk of recurrence both before and after year 5. It is important to know your personal risk to best weigh all of the options presented by your doctor.

2. How long will you need to be on anti-estrogen therapy?

Many studies have suggested an additional 5 year course (after completion of the first 5 years) of anti-estrogen therapy may help some women. However, not every patient benefits from treatment. In clinical trials of patients who were recurrence-free at 5 years, about 3 to 5 out of 100 patients benefited from extending long-term, anti-estrogen therapies (e.g. Tamoxifen, Femara®, and Arimidex®) beyond 5 years. This is why it is also important to understand whether you personally are among the group of women who are likely to benefit from extended treatment.

Another important element to consider is how well you have tolerated the many possible side-effects of these anti-estrogen medicines during the first 5 years of treatment.
Individualize your treatment plan

Recently, treatment guidelines\(^1\) followed by many oncologists have recognized the importance of individualizing treatment for each patient after the first 5 years of therapy is complete. The personalization of treatment plan comes after an assessment of risk and how well an individual is tolerating therapy. Tests measuring the risk of breast cancer recurrence help provide information necessary for shared decision-making.

Although an additional 5 years of anti-estrogen therapy may help some women lower their risk of the cancer returning, anti-estrogen therapy is also known to be associated with multiple side effects that can impact quality of life, as well as safety issues, some of which may be serious.\(^1,11\)

If you are considering extending therapy beyond 5 years. . .

. . .weigh the risks vs. benefit

Discuss the potential benefits and risks of continuing treatment with your doctor, and be sure to tell your doctor if you are experiencing any discomfort or symptoms. Keep all appointments with your care team and take your medications as prescribed by your doctor. It is important to weigh the RISK of the cancer returning vs. the potential BENEFITS and possible SIDE EFFECTS of continuing anti-estrogen therapy beyond 5 years.

Continue reading for more information, including a list of questions to ask your doctor, to help you individualize your treatment decision beyond 5 years.
Reported side effects include, but are not limited to:\textsuperscript{12}

<table>
<thead>
<tr>
<th>Potential Side Effects</th>
<th>Aromatase Inhibitors</th>
<th>Tamoxifen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Long-term Safety Concerns</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Bone fractures</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Cataracts</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Blood clots</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td><strong>Day-to-Day Tolerability Issues</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal dryness, itchiness and discharge</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Hot flashes/night sweats</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Joint stiffness/pain</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Muscle pain</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Sexual dysfunction</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

I thought, I can't do this anymore. I'm miserable. The thought starts to go through your head, is breast cancer worse than having the side effects that I'm having from this drug? When I learned about Breast Cancer Index, I thought, I have got to have this test, because I need this information - am I likely to benefit from another 5 years of this medicine? And if I am, maybe I'll soldier through and I'll go ahead and take it for another 5 years. But when I got my results, I could have danced on the ceiling. I was so happy to know that I wasn't going to have to take this medicine that had really changed my life in some ways that I didn't like.

Mary Darden, Nurse Practitioner and Breast Cancer Survivor

Note: The statement above reflects an individual’s personal views and interpretation and is not intended to convey a specific product intended use or utility based on clinical validation.

To see Mary's full story and other patient experiences, visit answersbeyond5.com
Breast Cancer Index® (BCI) is a test that provides two important pieces of information for shared decision-making to help you and your doctor decide whether to extend or end anti-estrogen therapy after 5 years.

1. **Your Risk of Recurrence**
   - Overall (years 0-10) & Beyond 5 Years (years 5-10)

   Breast Cancer Index determines your individual risk of recurrence by evaluating the biology of your original tumor biopsy and assessing several genes associated with cell proliferation and the estrogen signaling pathway\(^{13-15}\).

2. **Your Likelihood of Benefit from Anti-Estrogen Therapy**

   The test also examines the ratio of two genes associated with the estrogen signaling pathway to predict whether or not you are likely to benefit from continuing therapy beyond 5 years.\(^{16}\)

---

**Understanding your Breast Cancer Index report**

A Breast Cancer Index report will be sent to your healthcare provider with the following information:

- **Risk of Recurrence Beyond 5 Years**

  The Breast Cancer Index test report will provide your individual percent risk of the cancer returning and will tell you whether you are considered at Low Risk or High Risk of having the cancer return after 5 years.

- **Likelihood of Benefit from an Additional 5 Years of Anti-Estrogen Therapy**

  The Breast Cancer Index test report will also indicate whether you have a High Likelihood or Low Likelihood of benefiting from continuing anti-estrogen therapy for a full 10 years.
Is the Breast Cancer Index® (BCI) test right for me?

Breast Cancer Index may be right for you if you are looking for more information to help you and your doctor decide between your different options beyond year 5 and you:

- Were diagnosed with early-stage, estrogen receptor positive (ER+) invasive breast cancer
- Are pre- or post-menopausal and are lymph node negative (LN-) or lymph node positive (LN+) with 1-3 positive nodes
- Want additional information about your personal risk of recurrence after 5 years (~1 out of 3 women classified as clinically low risk by traditional methods were identified by BCI as having a higher risk of recurrence after 5 years)

When should I ask for the test?
If you and your healthcare provider are making a decision about how long to continue your anti-estrogen therapy, BCI provides important information that can help you with decision-making. This decision may occur at different time points depending on when you were diagnosed.

Looking ahead to plan your treatment after 5 years?
Approaching the 5 year mark & deciding with your doctor whether you should continue or end treatment?
Beyond 5 years wondering if you should continue to 10?

Questions to ask yourself:

- Do I want to know if anti-estrogen medications are likely to help keep my cancer from recurring?
- Did I take my anti-estrogen medication as it was prescribed before?
- How bothersome were my side effects before?
- How willing am I to tolerate an additional 5 years of side effects?
- Do I have risk factors for any other conditions or complications to consider before making this decision?
- How do I weigh the risk of cancer returning with the potential benefit and side effects of therapy?

Questions to ask your Oncologist:

- What is my personal risk of breast cancer coming back after 5 years?
- How is my risk of late recurrence measured?
- Can the cancer be prevented from coming back? How?
- Are you recommending I continue or stop my treatment after 5 years?
- Will the medication work for me? How long will I need to take it?
- Is there new data?
- What are the potential side effects of the medication?
- Will my side effects be worse than before?
- Are there any long-term health concerns related to taking this medication for an extended period of time?
- Which test is best suited to help answer these questions and assist with decision-making?

Congratulations on planning ahead for the next step!
How do I get the test?

Breast Cancer Index® is a one-time test that can provide information to help you and your doctor personalize your treatment plan.

A simple 3-step process is all that is required:

1. Ask your healthcare provider about ordering Breast Cancer Index for you. Note that only a licensed physician or other authorized healthcare provider may order the test.

2. Your original tumor tissue will be sent to the lab at Biotheranostics, the only lab that offers Breast Cancer Index.

3. Your provider receives your personalized report in just 7 days once we have received your tumor tissue and all required information necessary for processing your test.

Existing tissue from your original tumor biopsy is sufficient for testing with Breast Cancer Index. No additional biopsy is required; all your doctor has to do is order the test and wait for the results!

A recent study\(^{18}\) showed that patients whose care included incorporation of the BCI test results reported:

- A change in treatment preference
- Decreased anxiety and internal conflict regarding the decision
- Less concern about the cost of medicine, treatment safety, and whether or not the medicine would work
- Improved acceptance of the treatment plan
Introducing a program designed to involve you, the patient, in the decision to move forward with Breast Cancer Index testing

If your doctor has already ordered Breast Cancer Index to help determine whether or not continuing anti-estrogen treatment after 5 years may be right for you, a Patient Advocate will be reaching out to walk you through what to expect regarding the billing process and get your approval before we begin testing. Please respond to this outreach to avoid testing delays.

Biotheranostics helps make the billing process easy

We understand that every patient has a unique insurance coverage plan and our Patient Advocate Team strives to ensure a positive experience by navigating you through the insurance process.

How it works

1. Patient Access First team members will contact you directly to discuss the billing process and our Patient Assistance Program.
2. A team member will discuss any potential financial liability associated with BCI before beginning testing.
3. It will be your choice to continue with testing.

Note: We will attempt to contact you 3 times; if we are unable to reach you with these 3 attempts, we will assume that you wish to move forward with testing. For expedited service, please call us at (844) 319-8111.

What to expect

- Breast Cancer Index is reimbursed by many commercial insurance companies.
- Medicare covers Breast Cancer Index at a predetermined rate with no fees charged to you (based on specific coverage criteria).*
- A Financial Assistance Program is also available when certain criteria are met.

Financial Assistance

- The Financial Assistance Program is designed to assist any patient who has private payor insurance or who has no insurance.
- The majority of patients who are pre-qualified by our Patient Advocate Team and who apply for the Program will receive Financial Assistance.
- Based on the Program criteria, our Patient Advocate Team will communicate the final out-of-pocket cost to patients who qualify for Assistance.

Ultimately, the choice will be yours to proceed with testing

*Please visit the Billing & Insurance page on AnswersBeyond5.com for complete Medicare coverage criteria.
Commonly Asked Questions

Q: How do I qualify for the Biotheranostics Patient Assistance Program?

We will ask you to complete an application to determine if you qualify for assistance based upon your size of household, proof of net income and the current Federal Poverty Level guidelines. Our Patient Advocate team members will assist you with this form and provide a verbal outcome of your pre-qualification prior to testing. Once the test has been performed and your proof of income has been documented, you will be notified of the amount of financial assistance available to you and your final financial responsibility.

Q: When is a final decision made about the amount I will owe for the test?

If you are insured: When your insurance company has finished processing the claim for the test that was performed, it will send you a notice (Explanation of Benefits or “EOB”; Note this is NOT a bill) of the amount you are responsible for after deductibles, co-payments and co-insurance have been paid. If you receive a billing statement for your BCI, also included will be an application for our Financial Assistance Program, should you wish to apply at that time.

If you are uninsured: A determination will be made after all required information, including your application and documentation of income, has been received.

Q: Can the Company guarantee to me that I will not pay the full cost of the test?

By law, reference laboratories may not routinely waive patient responsibility for tests that are ordered for you. What you ultimately have to pay for the test is impacted by the terms of your insurance or health plan, the status of unmet deductibles, co-pays/co-insurance and the factors evaluated in our Financial Assistance Program. If you qualify and are formally approved, you will be notified of the amount of financial assistance available to you.

Still have questions about Patient Access FIRST?

Contact our Patient Advocate Team

Call us at (844) 319-8111

Email us at PatientAdvocates@biotheranostics.com

Visit us at AnswersBeyond5.com
Additional resources

Want more information about breast cancer treatment options, and support? Our partners provide helpful online resources and support for the breast cancer community.

- BeWisERaboutbreastcancer.org
- Breastcancer.org
- Tigerlilyfoundation.org
- Living Beyond Breast Cancer: LBBC.org
- URawarrior.com
- Young Survival Coalition (YSC)

REFERENCES

For full prescribing information including side effects go to:

The content, products and services discussed in this brochure are offered to educate consumers on health care and medical issues that may affect their daily lives and should not be considered, or used as a substitute for, medical advice, diagnosis or treatment. You should always talk to your health care provider for diagnosis and treatment information, including your specific medical needs, and to answer any questions regarding personal health or medical conditions. Statements reflect the interviewee’s personal views and interpretation and are not intended to convey a specific product intended use or utility based on clinical validation. The Breast Cancer Index test is not a companion diagnostic cleared or approved by the FDA; and it does not determine whether or not a specific drug will be beneficial to a specific patient.

©2019 Biotheranostics, Inc. BREAST CANCER INDEX is a registered trademark of Biotheranostics, Inc. All other registered trademarks or trademarks are property of their respective owners.
BCI Intended Use and Limitations

The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+: with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 to perform high complexity clinical laboratory testing.